The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

##STR00001##

Compounds of formula (I), formula (II), or formula (III) and their use with a neurological or psychiatric disorder, mediated by Kv11.1-3.1 containing potassium channels, including schizophrenia, are disclosed.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the α-position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP.sub.3.

##STR00001##

Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system diseases; and a medicine containing the pyridazinone derivative and/or the pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof.

##STR00001##

[In the formula, M.sup.1 represents a saturated or partially unsaturated C.sub.4-12 carbocyclic group or the like; R.sup.1 and R.sup.2 independently represent a hydrogen atom or the like; M.sup.2 represents a group represented by formula (2a) or the like; X.sup.1a, X.sup.1b and X.sup.1c independently represent N or the like; X.sup.2, X.sup.3 and X.sup.4 independently represent CR.sup.3 or the like; A.sup.1 and A.sup.2 independently represent N or the like; and R.sup.3 represents a hydrogen atom or the like.]

The present invention relates to a method for the preparation of an N-monofluoroalkyl tropane, a method for the preparation of a trialkyltin tropane, a method for the preparation of an iodinated and/or radioiodinated tropane and the use of the N-monofluoroalkyl tropane as a precursor in the method for the preparation of the trialkyltin tropane and/or the iodinated and/or radioiodinated tropane.

The present invention relates to a method for the preparation of an N-monofluoroalkyl tropane, a method for the preparation of a trialkyltin tropane, a method for the preparation of an iodinated and/or radioiodinated tropane and the use of the N-monofluoroalkyl tropane as a precursor in the method for the preparation of the trialkyltin tropane and/or the iodinated and/or radioiodinated tropane.

A bridged heterocyclyl-substituted pyrimidine compound, a preparation method therefor, and pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method for the compound, a pharmaceutical composition containing the compound, use of the compound as a JAK1 and TYK2 kinase inhibitor, and use in treating diseases related to JAK1 and TYK2 kinase activity, such as inflammations, autoimmune diseases, and cancers. The definition of each substituent in general formula (I) is the same as that in the description.

##STR00001##

A bridged heterocyclyl-substituted pyrimidine compound, a preparation method therefor, and pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method for the compound, a pharmaceutical composition containing the compound, use of the compound as a JAK1 and TYK2 kinase inhibitor, and use in treating diseases related to JAK1 and TYK2 kinase activity, such as inflammations, autoimmune diseases, and cancers. The definition of each substituent in general formula (I) is the same as that in the description.

##STR00001##